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After emerging from the thymus, naive CD4 T cells circulate through secondary lymphoid 
tissues, including gut-associated lymphoid tissue of the intestine. The activation of naïve 
CD4 T cells by antigen-presenting cells offering cognate antigen initiate differentiation 
programs that lead to the development of highly specialized T helper (Th) cell lineages. 
Although initially believed that developmental programing of effector T cells such as T 
helper 1 (Th1) or T helper 2 (Th2) resulted in irreversible commitment to a fixed fate, 
subsequent studies have demonstrated greater flexibility, or plasticity, in effector T cell 
stability than originally conceived. This is particularly so for the Th17 subset, differenti-
ation of which is a highly dynamic process with overlapping developmental axes with 
inducible regulatory T (iTreg), T helper 22 (Th22), and Th1 cells. Accordingly, intermediary 
stages of Th17  cells are found in various tissues, which co-express lineage-specific 
transcription factor(s) or cytokine(s) of developmentally related CD4 T cell subsets. A 
highly specialized tissue like that of the intestine, which harbors the largest immune 
compartment of the body, adds several layers of complexity to the intricate process of 
Th differentiation. Due to constant exposure to millions of commensal microbes and 
periodic exposure to pathogens, the intestinal mucosa maintains a delicate balance 
between regulatory and effector T cells. It is becoming increasingly clear that equilibrium 
between tolerogenic and inflammatory axes is maintained in the intestine by shuttling the 
flexible genetic programming of a developing CD4 T cell along the developmental axis 
of iTreg, Th17, Th22, and Th1 subsets. Currently, Th17 plasticity remains an unresolved 
concern in the field of clinical research as targeting Th17 cells to cure immune-mediated 
disease might also target its related subsets. In this review, we discuss the expanding 
sphere of Th17 plasticity through its shared developmental axes with related cellular 
subsets such as Th22, Th1, and iTreg in the context of intestinal inflammation and also 
examine the molecular and epigenetic features of Th17 cells that mediate these overlap-
ping developmental programs.
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iNTRODUCTiON
When an antigen-inexperienced CD4 T cell encounters its cognate 
antigen in the secondary peripheral lymphoid tissues, it differenti-
ates into T effector cells guided by a microenvironment consisting 
of a diversity of antigens, antigen-presenting cells (APCs), and 
other innate immune cells. Amidst the complex environment, 
lineage-specific fate decision of a naïve CD4 T cell toward dif-
ferentiating into a specialized T helper (Th) cell is contingent on 
several variable factors: (a) type of pathogen-associated molecular 
patterns (PAMPs), (b) types of APC, (c) strength of T cell receptor 
(TCR) stimulation, (d) strength of costimulation, (e) cytokine 
gradients, (f) nature of cytokine-induced signal transducer and 
activator of transcription factor (STAT) signaling, (g) induction 
of lineage-specific transcription factors (TFs), and (h) induction 
of lineage-associated TFs. Contingent on nature of these variable 
factors, naive CD4 T cell can be programmed to T helper 1 (Th1) 
cells producing IFNγ; T helper 2 (Th2) cells producing IL-4, 
IL-5, and IL-13; Th17 cells producing IL-17A/IL-17F; T helper 
22 (Th22) cells producing IL-22, or inducible regulatory T (iTreg) 
cells producing IL-10 (1, 2). Not only these subsets are charac-
terized by the signature cytokine(s) they produce, each subset 
is regulated by the induction of a distinct “lineage-specific” or 
“master” TF. T-box protein expressed in T cells (T-bet), GATA 
binding protein 3 (Gata-3), aryl hydrocarbon receptor (AhR), 
retinoic acid-related orphan receptor gamma t (RORγt), and 
Forkhead box P3 (FoxP3) are lineage-specific TFs of Th1, Th2, 
Th22, Th17, and iTreg cells, respectively (3–8). Before the induc-
tion of the lineage-specific TF, members of the STAT protein 
family transmit cytokine-mediated signals and kick-starts the 
initiation of Th differentiation. Out of the seven STATs identified 
in mouse, STAT1/STAT4, STAT6, STAT3, and STAT5a/b play 
non-redundant functions in differentiation of Th1, Th2, Th17, 
and iTreg cells, respectively (9–16). Once each lineage is “fixed” 
into a committed phenotype, they are expected to grow clonally 
in a deterministic way without any change of lineage fate.
Despite its relevance, the standard “2-factor” model of Th 
lineage differentiation, consisting of STAT and master TF-driven 
differentiation, underscores the multifactorial complexity of Th17 
differentiation. Besides the requirement of RORγt, the lineage-
specific TF for Th17 differentiation, multiple lineage-associated 
TFs also play critical roles in regulating Th17 differentiation. 
CD4 T  cell deficient in several TFs such as RORα, AhR, IRF4 
(Interferon regulatory factor 4), and BATF (Basic Leucine Zipper 
ATF-like TF) also show attenuated Th17 differentiation that 
cannot be restored by overexpression of RORγt (16–22). More 
recently, IRF4 and BATF have been designated as “pioneer” TFs 
that act downstream of TCR signaling and bind to the promoters 
of Il17a/Il17f genes for regulating their chromatin accessibility 
to lineage-specific TFs at the region (23). Therefore, the growing 
layers of complexity overwhelms the linear narrative of Th17 
differentiation as we now appreciate the inherent phenotypic 
instability or “plasticity” of the Th17 subset that is evident from 
presence of intermediate phenotypes in various organs, including 
the intestine.
In the intestine, CD4 T cell differentiation is a highly intricate 
process. Retinoic acid (RA), a vitamin A metabolite produced 
by intestinal APCs, is a principal co-factor that promotes iTreg 
development and inhibits Th17 development (24, 25). Even in 
presence of IL-6 and TGFβ, RA strongly counteracts Th17 devel-
opmental program by reciprocally favoring iTreg development 
(15, 25, 26). However, despite the robust production of RA by 
intestinal APCs, the greatest number of Th17 cells develops in the 
intestine under inflammatory conditions (27). Therefore, it is per-
plexing how CD4 T cells undergo vigorous Th17 differentiation 
in a microenvironment that is replete with Th17-counteracting 
mediators that support iTreg development. Interestingly, a sub-
stantial percentage of Th17 cells in the intestinal lamina propria 
express FoxP3 at some point during their development indicating 
a dynamic relationship between the iTreg and Th17 cells (28).
Like Th17 and iTreg cells, Th22 cells, which secrete IL-22 with-
out IL-17 coproduction, are also found in the intestine during 
inflammation (8). Similar to iTreg cells that share TGFβ signaling 
with Th17 cells, Th22 cells share a developmental pathway with 
Th17  cells due to their common developmental requirement 
for IL-6 (Figure 1). Although Th17 cells were initially believed 
to be the primary source of IL-22, clear functional differences 
between Th17 and Th22 cells are evident, as transferred Th22 
cells, but not Th17 cells, are able to rescue susceptible mice from 
enteropathogenic bacterial infection (8). It is intriguing how 
Th17 and Th22 cells co-evolve in the intestinal environment 
that is rich in TGFβ—a cytokine that also negatively regulates 
Th22 differentiation. Another prominent Th subset, which has 
developmental ties with the Th17 pathway, is the Th1 subset. 
Unlike Th22 and iTreg cells, proximal signaling events guiding 
“classical” Th1 differentiation are distinct from Th17  cells. Yet, 
differentiated Th17 cells frequently transit to “Th1-like” popula-
tions under inflammatory conditions of the intestine (29–31). 
During autoimmune colitis, transferred Th17 population rapidly 
transit to T-bet-expressing Th1-like Th17 cells leading to aggra-
vated autoimmune response (31). These Th17-derived, Th1-like 
cells are recognized as a principle pathogenic effector population 
in several autoimmune diseases, including inflammatory bowel 
disease (IBD). Although several factors that contribute to the late 
developmental transition of Th17 precursors to Th1-like cells 
have been identified, details of how the late developmental axis of 
Th17 cells overlaps with Th1 cells despite apparent developmental 
dissimilarities between these two subsets remain to be defined. 
Due to this intrinsic developmental link of Th17 cells with iTreg, 
Th22, and Th1 cells, a complex dynamic interaction takes place 
among different cytokine-induced TFs, lineage-specific TFs, and 
lineage-associated TFs during Th17 differentiation that strongly 
influences the fate commitment and plasticity of Th17 cells. This 
indicates a complex, multifactorial decision-making process 
during Th17 lineage commitment, warranting detailed study of 
the developmental relationship with related subsets, which will 
be discussed in this review.
“NON-CYTOKiNe” FACTORS 
iNFLUeNCiNG TH17 FATe COMMiTMeNT
When a naïve CD4 T  cell engages with APC via TCR–pMHC 
complex, the fate of Th differentiation is broadly dictated by 
FiGURe 1 | Shared axes of Th17 differentiation. Developmental axis of Th17 subset substantially overlaps with developmental axes of iTreg, Th22, and Th1 
subsets of T helper cells. While the origin of Th17 differentiation is intrinsically linked with iTreg cells due to their common requirement of TGFβ signaling, Th17 
differentiation is also linked with Th22 subset due to the shared requirement of IL-6 signaling. Although proximal signaling events guiding Th17 differentiation are 
distinct from the Th1 subset, late developmental axis of Th17 is overlapping with Th1 cells as chronic TCR stimulation or action of IL-23 or IL-12 readily converts 
mature Th17 cells to IFNγ-producing “Th1-like” cells. Accordingly, along the entire developmental axis of Th17 and its related subsets, intermediate phenotypes 
co-producing FoxP3/IL-17, IL-17/IFNγ, and IL-17/IL-22 are found in vivo that can perform beneficial or pathogenic functions depending on the nature of the 
disease. While IL-2 and retinoic acid (RA) are negative regulators of iTreg–Th17 axis that oppose Th17 differentiation while promoting iTreg differentiation, TGFβ 
negatively regulates the Th17–Th22 axis as well as the Th17–Th1 axis by suppressing Th22 and Th1 cellular differentiations while facilitating iTreg and Th17 
differentiations. 
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“non-cytokine” factors as well as by “cytokine-induced” TFs 
(Figure  2). The complex system of molecular communications 
from non-cytokine factors initially predisposes the naïve CD4 
T cells to a specific differentiation pathway prior to the action of 
cytokine. The non-cytokine factors that influence Th17 differen-
tiation are as follows: (a) nature of microbial antigen or PAMP, (b) 
nature of APC, (c) strength of TCR–pMHC interaction, and (d) 
strength of costimulation.
PAMP and APC
Pathogen-associated molecular patterns (PAMPs) present on 
the cell wall or cell membrane of microbes stimulate APC in 
different ways to induce a wide variety of cytokines. Human 
monocytes pulsed with the fungus Candida albicans and the 
bacteria Staphylococcus aureus produce IL-6, TNFα, and IL-23, 
whereas IL-12 is induced exclusively by the fungus but not by the 
bacteria (32). Therefore, fungal antigens, not bacterial antigens, 
specifically stimulate APCs to produce IL-12, resulting in the 
conversion of naïve CD4 T cells into fungus-specific Th17 cells 
that produce both IL-17 and IFNγ. Moreover, β-glucan, a major 
PAMP isolated from fungal cell wall, induces production of an 
inflammatory lipid mediator, Prostaglandin E2 (PGE2), which 
plays a pivotal role in Th17 differentiation (33). Inhibition 
of PGE2 synthesis drastically reduces IL-23 production by 
β-glucan-activated APCs, suggesting that endogenous PGE2 
amplifies IL-23 synthesis in response to the C. albicans-associ-
ated PAMP. Besides the specificity of PAMPs on microbes, the 
specificity of the T cell activating stimulus also depends on the 
type of APC recruited to the site of interaction. For example, 
intestinal CD103+ DCs are much more efficient than CD103− 
DCs in TGFβ-mediated conversion of naive CD4 T  cells into 
iTreg cells. This is due to their specialized capacity to produce 
higher levels of retinaldehyde dehydrogenase (RALDH2), which 
enables them to convert retinal, a Vitamin A derivative, into RA 
(24, 25). Accordingly, intestinal CD103+ DCs, not splenic DCs, 
inhibit Th17 differentiation and facilitate iTreg development by 
overcoming the Th17-promoting effect of IL-6 (25). Moreover, 
some APCs can also preferentially induce specific cytokines that 
block Th17 differentiation. Type 1 IFN-secreting plasmacytoid 
DCs inhibit Bordetella pertussis-specific Th17 differentiation 
leading to exacerbation of respiratory disease (34). As TLR7/
TLR9 is preferentially expressed in plasmacytoid DCs, it is likely 
that TLR7/TLR9-activating PAMPs on the pathogen promote 
IFNα secretion from plasmacytoid DCs, which inhibits Th17 
differentiation by the suppressive effects of STAT1 signaling 
induced by Type I IFNs (35–37).
FiGURe 2 | Non-cytokine Factors and Cytokine-induced Transcription Factors Governing Th17 Plasticity. The fate of Th17 differentiation during the 
journey of a naive CD4 T cell towards becoming an antigen-specific Th17 cell can be broadly dictated by “non-cytokine” factors and “cytokine-induced” 
transcription factors (TFs).  Among “non-cytokine” factors, strength of TCR–pMHC engagement, strength of co-stimulation, nature of pathogen-associated 
molecular pattern or PAMP–TLR interaction, and nature of APC impact plasticity of Th17 cells. Moreover, the microenvironment of APC–T cell interaction also guides 
Th17 lineage commitment. An environment rich in retinoic acid (RA) or TGFβ, which prevails in the intestine, also influences Th17 plasticity. The entire landscape of 
Th17 programing that is initiated by “cytokine-induced” TFs can be divided into three sequential terrains (orange, blue, and green). During its journey through the first 
terrain, TCR signaling coupled with co-stimulation and other “non-cytokine” factors cooperate with APC-generated cytokines to induce STAT proteins (STAT3, 
STAT1, STAT4, and STAT5) and “pioneer” TFs like BATF and IRF4 (Orange). The STAT proteins and the pioneer TFs then jointly initiate the lineage-specific 
developmental programing by inducing STAT-responsive and IRF4/BATF-responsive genes, which include activation of master TF (RORγt) of Th17 cells. During its 
transition through the second terrain, STAT protein-induced RORγt jointly cooperates with the “pioneer” TFs to alter chromatin accessibility of key Th17-specific 
genes by epigenetic modification (Blue). During this point of time, the lineage-associated TFs are also induced during Th17 differentiation by both “non-cytokine” and 
“cytokine-mediated” signaling. In the final terrain of Th17 programming, an orchestration of complex networking of signaling events modulated by the lineage-
specific TF (RORγt) in association with lineage-associated TFs (e.g., c-Maf, AhR, Runx1, etc.) determine the stability of the Th17 developmental program through 
integration of various additional pro-inflammatory and anti-inflammatory environmental cues. Although STAT3-induced RORγt predominantly drives Th17 
programing, other STAT proteins (like STAT1, STAT5) and TFs (like T-bet and FoxP3) that alters Th17 lineage stability are also induced contingent on the initial 
priming environment. Lineage commitment or plasticity of Th17 cells is the outcome of the interplay of these variable factors acting across all the three levels.
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Strength of TCR–pMHC interaction
Strength of TCR stimulation is another independent variable 
influencing Th lineage commitment. Peptide/MHC complexes 
that interact more strongly with TCR favor generation of Th1-
like cells, while those that bind weakly favor Th2-like cells as 
low concentration of peptide increases GATA3 expression 
to facilitate Th2 differentiation (38). Compared to wild-type 
peptide, mutant human collagenase IV peptides with weaker 
affinity for their cognate TCR also elicit an IL-4-producing Th2 
response while mutant peptides with higher affinity prime an 
IFNγ-producing Th1 response (39). Weaker affinity-driven Th2 
response might be advantageous to an organism, as autoreactive 
T cell clones emerging from thymic selection at the lower end of 
affinity spectrum will either be anergic or release Th2 cytokine, 
thereby limiting the extent of inflammatory damage. However, 
conflicting findings exist regarding the role of TCR strength on 
Th17 differentiation. In mouse model, decreased strength of 
TCR stimulation preferentially reduced IL-17A expression in a 
5Bhaumik and Basu Developmental Plasticity of Th17 Differentiation
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 254
calcineurin/NFAT-dependent manner (40). Moreover, despite 
being exposed to Th17-promoting cytokines, naïve CD4 T cells 
receiving weak TCR signals preferentially express FoxP3 and 
resist differentiation to Th17 pathway (41, 42). Accordingly, defi-
ciency of Tec family tyrosine kinase Itk, which is activated upon 
TCR signaling, results in impairment of Th17 differentiation with 
their concomitant divergence to FoxP3-inducible iTreg cells (43). 
However, Itk deficiency in CD4 T cells, besides defective NFATc1 
sssdifferentiation under low avidity TCR stimulation (44). This 
raises the possibility that downstream signaling pathways contin-
gent on TCR signaling strength can predispose differentiation of 
a naïve CD4 T cell along iTreg/Th17/Th1 axis.
In apparent contrast, low-strength stimulation of CD4 T cells 
has also been shown to favor a Th17 response that is explained 
by a failure of high-strength TCR-activated Th17 cells to induce 
binding of NFATc1 to the IL-17 promoter (45). NFATc1 has been 
reported to be a crucial TF for regulating IL-17 promoter activity 
in response to TCR signaling.
Interestingly, high induction of IFNγ also takes place along 
with IL-17 in low-strength TCR-stimulated Th17 cells, suggesting 
that TCR strength plays a role in plasticity of Th17 cells. Repetitive 
TCR stimulation can also facilitate transition of Th17  cells 
to Th1  cells (29). Hence, both along the early iTreg–Th17 and 
late Th17–Th1 developmental axes, TCR signal strength is one 
of the contributory factors in determining Th17 plasticity. In 
conclusion, both affinity and dose of the antigen via strength of 
TCR stimulation are instrumental to bias initial programing of 
differentiation of a developing antigen-experienced CD4 T cells 
toward a particular Th lineage.
Strength of Costimulation
Besides TCR signal, differentiation of naive T lymphocytes into 
effector cells requires additional signals provided by costimula-
tory pathways mediated by B7:CD28 and CD40:CD40 ligand 
(CD40L) interactions. CD28 costimulation plays a critical role 
along the iTreg–Th17 axis of differentiation. Lack of CD28 
costimulation impairs the ability of naïve T cells to differentiate 
into iTreg cells in the periphery in an IL-2-dependent manner 
(46, 47). Conversely, high CD28 costimulation inhibits Th17 
development indicating that strength of CD28-B7 engagement 
can reciprocally modulate the differentiation of naïve CD4 T cells 
along the iTreg–Th17 developmental axis (48). As strong costim-
ulation amplifies IL-2 induction that is known to inhibit Th17 
differentiation, it is likely that strength of CD28 stimulation can 
negatively influence Th17 differentiation while facilitating iTreg 
differentiation via an IL-2/STAT5-dependent pathway. Besides 
CD28 costimulation, CD40–CD40L crosstalk is required for opti-
mal Th17 differentiation. Although IL-12 production from DC is 
one of the mechanisms by which CD40-mediated signaling exerts 
its influence on priming of effector T cells, the requirement of 
CD40–CD40L interaction between APCs and T cells also involves 
other mechanisms such as production of other cytokines from 
DCs in a contextual manner (49, 50). During Th17 differentia-
tion, a complex interaction between strong antigenic signals and 
PAMP-dependent pathogenic stimuli induce CD40L expression, 
which increases IL-6 production from DCs for facilitating Th17 
differentiation (41). Upon T  cell priming by zymosan-exposed 
Cd40−/− DCs, Th17 expansion is partially rescued by addition of 
exogenous IL-6. Accordingly, immunization of Cd40−/− mice with 
a high antigen dose results in an impaired Th17, but not Th1 dif-
ferentiation. Therefore, the strength of costimulation along with 
strength of TCR engagement and nature of PAMP can predispose 
an antigen-experienced CD4 T cells toward a specific lineage.
CYTOKiNeS AND CYTOKiNe-iNDUCeD 
TRANSCRiPTiON FACTORS 
iNFLUeNCiNG TH17 FATe COMMiTMeNT
Decades ago, it was conceptualized that activated T cell clones 
preferentially producing IFNγ are Th1 subsets that are instrumen-
tal in eliminating intracellular pathogens, while those producing 
IL-4, IL-5, and IL-13 are Th2 subsets that play a vital role in 
expelling extracellular helminths (51, 52). This selective cytokine 
production was thought to be stable as clonally propagated Th1 
or Th2 clones continued to produce their signature cytokines 
without any inter-conversion or fate reversal (53). Although the 
discovery of Th1/Th2 subsets of CD4 Th cells revolutionized our 
understanding of adaptive immune response, it also fostered a 
rigid picture of the stability of these cells (53, 54). Currently, the 
situation we confront is more complex. IFNα, IFNγ, and IL-12 
are now considered to be key innate cell-derived modulators of 
Th1 differentiation, while IL-25, IL-33, and thymic stromal lym-
phoprotein (TSLP) are key innate immune cell-derived cytokines 
governing Th2 differentiation (55–58). The CD4 T cell repertoire 
was substantially expanded with the discovery of iTreg, Th17, 
and Th22 cells. At present, Th17 differentiation is emerging as a 
highly complex process involving multiple cytokines and TFs that 
outnumber other lineages such as Th1 and Th2 subsets. Whereas, 
IL-6 and TGFβ constitute the primary cytokines initiating Th17 
development, IL-21, IL-1β, and IL-23 play distinct roles in guid-
ing the Th17 differentiation process to a committed state. While, 
RORγt and STAT3 are essential TFs required for Th17 lineage 
differentiation, other TFs such as AhR, IRF4, BATF1, and Runx1 
are also required to regulate optimal Th17 development.
The Critical Axis of iL-6/iL-21/STAT3/
RORγt
IL-6, an acute phase protein, is a critical differentiation factor 
for the generation of Th17 cells (27, 59). Binding of IL-6 to its 
co-receptors IL-6R and gp130 results in activation of STAT3, 
which induces IL-17 via activation of RORγt (19, 60). In STAT3-
deficient CD4 T cells grown under Th17 polarizing conditions, 
there is complete abrogation of IL-17 induction. Therefore, both 
STAT3 and RORγt co-operatively induce optimal expression 
of IL-17 (19). As overexpression of RORγt alone is sufficient to 
direct Il17 transcription in the absence of exogenous cytokine, it 
is considered as the “master” TF of Th17 cells. However, besides 
direct transcriptional activation of Il17a/Il17f locus, other 
critical functions of RORγt during Th17 development are poorly 
understood. Despite the critical importance of STAT3 in Th17 
differentiation, its overexpression fails to induce optimal Th17 
differentiation in absence of RORγt, suggesting that STAT3 co-
operates with RORγt to induce optimal Th17 differentiation (19).
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IL-6 also induces the production of IL-21 in Th17  cells, 
which can, in turn, induce expression of IL-23R, subjecting 
Th17 cells to the effects of IL-23 (19). Although the generation 
of Th17 cells is reported to be impaired in the absence of IL-21 
signaling, Th17 cells can develop in the absence of IL-21/IL-21R 
signaling (61–64). It is likely that IL-21 influences pathogenic-
ity of Th17  cells in autoimmune diseases by enhancing the 
effect of IL-23 on Th17 cells, which promotes Th1 competence 
of Th17 cells. Curiously, an IL-6-independent pathway of Th17 
development has also been demonstrated specifically in tissues 
where RA is absent. In Il6−/− mice, Th17 cells were detected in the 
peripheral secondary lymphoid organs but not in the intestinal 
lamina propria where RA is produced at a higher concentration 
(65). It seems that due to copious production of RA by resident 
CD103+ DCs in the intestine, IL-6 becomes essential for Th17 
development as it overcomes the suppressive effect of RA on Th17 
differentiation.
We have recently demonstrated that IL-6 alone is critically 
required, but not sufficient to overcome RA-mediated suppres-
sion of Th17 differentiation (26). Short-lived STAT3-induction by 
IL-6 inadequately opposes RA-driven STAT5 induction resulting 
in suppression of Th17 differentiation in presence of IL-6 both 
in vitro and in the intestinal lamina propria during acute intestinal 
inflammation. STAT3 activation is also a dominant mechanism 
to suppress FoxP3 expression during Th17 differentiation. The 
suppressive effect of STAT3 on FoxP3 is independent of RORγt, as 
STAT3-deficient Treg cells fail to downregulate FoxP3 expression 
in presence of IL-6, while RORγt-deficient Treg cells are able to 
downregulate FoxP3 in presence of IL-6 (66). However, studies 
from our group have shown that only in intestinal tissue where 
RA has a dominant presence, transient nature of IL-6-induced 
STAT3 fails to downregulate FoxP3 expression due to strong 
STAT5-depenedent FoxP3-activating property of RA (26). In 
other tissues devoid of high levels of RA, STAT3 activation by 
IL-6 efficiently represses FoxP3 transcription. Therefore, whereas 
both STAT3 and RORγt are critical for IL-17 expression, STAT3 
alone is sufficient for effective suppression of FoxP3. In the con-
text of a tissue environment such as the intestinal mucosa, where 
both TGFβ and RA are produced in abundance to facilitate iTreg 
programming, STAT3 signaling might be vital to attenuate FoxP3 
expression for favoring Th17 development.
Interestingly, in addition to its STAT3 activating potential, 
IL-6 also activates STAT1 in CD4 T cells (67–69). Under Th17 
differentiation conditions, Stat3−/− CD4 T cells assume a Th1 phe-
notype, suggesting that STAT3 is a master regulator that skews 
Th17 responses away from Th1 pathway (19, 70). Accordingly, 
activated lamina propria lymphocytes from STAT3-deficient mice 
generate a robust Th1 response that is several folds higher than 
WT mice along with a completely abrogated Th17 response (70). 
It is likely that besides its role in induction of Il17a/f transcription, 
STAT3 also participates in regulating Th17 plasticity as it counter-
regulates Th1 programing during Th17 differentiation. STAT3 also 
drives positive epigenetic modifications of its target genes during 
Th17 development. STAT3-bound genes such as Il17a, Il17f, Il21, 
and Il6ra contain permissive chromatin marks in WT cells, but 
these marks are absent or reduced in Stat3-deficient Th17 cells 
(71). Although IL-6 does not appear to be required to maintain 
a stable Th17 phenotype post-differentiation, a role for on-going 
STAT3 signaling cannot be excluded in regulating plasticity of 
Th17 lineage (29). It remains a distinct possibility that in addition 
to directly program CD4 T cells toward Th17 pathway via RORγt 
activation, STAT3 signaling also counteracts STAT1 activation, 
which is essential to prevent development of Th1 programming 
during Th17 development. Besides STAT3, RORγt also plays a 
role in Th17 stability as its overexpression leads to transcriptional 
repression of T-bet (72). The entire interaction between RORγt 
and T-bet forms a feedback loop during Th17 differentiation as 
T-bet, once expressed, also act directly to silence Rorc locus (72). 
Therefore, besides direct transcriptional activation of Il17 locus, 
it is likely that RORγt additionally opposes development of Th1 
programing and restricts plasticity of Th17 cells.
The Controversial Role of TGFβ
The concept of Th17 cells as a stable lineage has been brought into 
question following characterization of heterogeneous popula-
tions of IL-17A-producing CD4 T cells exhibiting various degrees 
of pathogenicity contingent on the initial milieu of differentiation 
(73, 74). One of the first reports describing IL-17-producing 
CD4 T cells as a discrete lineage observed that both IFNγ and 
IL-4 inhibited differentiation of Th17 cells (37). At the time of 
this discovery, TGFβ was already recognized as a cytokine that 
potently inhibited Th1 and Th2 cell differentiation by suppress-
ing T-bet and GATA3 TFs, respectively (75). Accordingly, TGFβ 
was found to be essential for optimal Th17 differentiation due 
to its combinatorial action of downregulating IFNγ- and IL-4-
induced signaling pathways (27). However, two independent 
reports noted that TGFβ is dispensable for differentiation of 
human Th17 cells (76, 77). Soon after, the dispensability of TGFβ 
in human Th17 differentiation was contested and three studies 
reestablished TGFβ as a critical factor, which works in concert 
with inflammatory mediators, including IL-1, IL-21, IL-6, and 
IL-23, for inducing human as well as mouse Th17 differentiation 
(78–80).
Remarkably, the dispensability of TGFβ in Th17 differentia-
tion resurfaced again when it was shown that there could be two 
pathways to Th17 differentiation. While one is dependent on 
TGFβ, which induces differentiation into “non-pathogenic” 
Th17  cells, the other is independent of TGFβ and induces dif-
ferentiation into “pathogenic” Th17  cells (74). It was shown 
that TGFβ-independent “pathogenic” and TGFβ-dependent 
“non-pathogenic” subsets of Th17 are phenotypically and 
functionally dissimilar, with more than 2,000 genes differentially 
expressed between the subsets. While RORγt was induced in both 
populations, T-bet was selectively upregulated in “pathogenic” 
Th17  cells, which showed much higher degree of plasticity in 
transitioning into Th1-like cells. This is likely due to the effects 
of TGFβ to potently suppress T-bet-driven Th1 development 
and restrict transition of TGFβ-dependent “non-pathogenic” 
Th17 population into Th1-like cells. Despite convincing proof 
of a TGFβ-independent Th17 developmental pathway linked 
to its pathogenic functionality, a conundrum still remains. The 
necessity of TGFβ-signaling in promoting Th17 differentiation 
was established by another study, which found that deletion of 
the Tgfb1 gene from activated T cells considerably impacted Th17 
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differentiation resulting in highly reduced frequency of IL-17-
producing cells (81). Moreover, TGFβ is widely expressed by 
immune cells and normal human subjects have >2 ng/ml TGFβ1 
in their plasma (82). Therefore, it is difficult to conceive of a tissue 
environment completely devoid of its presence. In both IBD and 
experimental autoimmune encephalomyelitis (EAE), Th17 cells 
grown in presence of TGFβ are also shown to be pathogenic, 
which clearly limits the correlation of TGFβ with non-pathogenic 
function of Th17 cells (29, 59, 83).
Nevertheless, one can imagine an inflammatory milieu where 
the concentration of TGFβ is kinetically altered during progres-
sion of inflammation, thereby creating a temporal concentration 
gradient of TGFβ. If a reduced concentration of TGFβ supports 
development of pathogenic inflammatory Th17 cells as a result of 
significant induction of T-bet, an altered environment facilitating 
high production of TGFβ might ensure homeostasis by convert-
ing the same subset into a non-pathogenic population by sup-
pressing or restricting high T-bet induction. Alternatively, a drop 
in concentration in TGFβ during course of inflammation might 
enable transition of a non-pathogenic Th17  cells into a T-bet 
co-expressing pathogenic subset. Either way, it indicates that 
inherent plasticity of Th17 cells can play a vital role in governing 
immune homeostasis. This line of reasoning might prompt one to 
think that fate commitment of Th17 cells is a dynamic phenom-
enon progressing through a series of intermediate developmental 
stages. Interestingly, population of Th17  cells found in the gut 
of Crohn’s disease (CD) patients are heterogeneous in nature. 
Subsets of Th17 cells have been isolated from gut mucosa of CD 
patients that co-produce IFNγ as well as FoxP3 (84, 85). The IL-17 
and FoxP3 co-expressing cells not only exhibit shared phenotypic 
characteristics of Th17 and iTreg cells but also show potent sup-
pressor activity in  vitro (86). Therefore, one cannot preclude 
the likelihood of developmental overlap among Th17, Th1, and 
iTreg cell lineages that links iTreg–Th17 axis with Th17–Th1 
axis of differentiation (2). It is tempting to hypothesize that in 
an inflammatory setting, contingent on immediate availability of 
TGFβ, Th17 differentiation lies in a dynamic flux between iTreg 
and Th1 differentiation, where the transitional iTreg/Th17 cells 
serve in a regulatory capacity while the Th17/Th1 cells are pro-
inflammatory in nature. Th17 cells that are early exposed to high 
levels of TGFβ assume a more committed Th17 phenotype due 
to suppression of T-bet compared to those developing under low 
concentration of TGFβ as they are less prone to conversion to 
IFNγ-co-producing Th17 cells.
The Accessory Roles of iL-23 and AhR
IL-23 was originally described as a cytokine closely related 
to IL-12 that induced IFNγ from human memory T  cells in a 
STAT4-dependent manner (87). Subsequently, IL-23 was her-
alded as a necessary cytokine for Th17 development as it was 
found that IL-23 has a dual capacity of inducing IL-17 as well 
as IFNγ (37, 88). Whereas IL-23 alone specifically induced IFNγ 
from CD4 T cells in presence of neutralizing antibody to IL-4, 
IL-23 induced modest IL-17 induction from CD4 T cells in pres-
ence of neutralizing antibody to both IL-4 and IFNγ (37). Later, 
it was found out that IL-23 is dispensable for Th17 development 
both in vitro and in vivo suggesting that IL-23 plays an accessory 
role in modulating Th17 effector function (27). Indeed, IL-23 
signaling promotes differentiation of pathogenic Th17 cells (73). 
The initial observation regarding kinship of IL-23 to the Th1-
inducing cytokine IL-12 and its ability to induce IFNγ via STAT4 
was further corroborated by studies examining the effect of IL-23 
on plasticity of Th17 cells. Differentiated Th17 cells continuously 
exposed to IL-23 deviate to a Th1-like phenotype (29). Moreover, 
CD4 T cells lacking IL-23R show a reduced emergence of IFNγ-
and IL-17-co-expressing phenotype and do not trigger colitis 
(89). Accordingly, the switch from Th17 to Th1-like cells depends 
on IL-23-driven induction of T-bet, indicating the essential role 
of IL-23 in mediating transition of Th17 into Th1 cells (30). With 
the use of IL-17A-eYFP reporter mice, which permanently marks 
IL-17A-producing cells, it was demonstrated in a fate-mapping 
study that the Th1 cells present in the lymph nodes and spinal 
cord of mice with EAE were all ex-IL-17A producers and IL-23-
deficient Th17 cells did not become Th1 cells.
While evidence of induction of RORγt by IL-23 is lacking, 
IL-23 plays a vital role in upregulating AhR (8, 22). AhR, a heter-
odimeric ligand activated TF, is also known to positively regulate 
Th17 development (22, 90). Although AhR is not required for 
initial differentiation of Th17 cells, it promotes their expansion 
and is essential for their production of IL-22. Activation of AhR 
by its natural ligand 6-formylindolo[3,2-b]carbazole (FICZ), 
a tryptophan derivative, increases both IL-17 and IL-22 from 
cultured Th17  cells. Unlike RORγt, forced expression of AhR 
into CD4 T  cells in the absence of cytokines does not lead to 
IL-17 or IL-22 expression. This suggests that signaling interme-
diates induced jointly by IL-6 and TGFβ co-operate with AhR 
to facilitate Th17 development. Intriguingly, AhR also regulates 
FoxP3 expression, suggesting its critical role in development 
of iTreg cells (91, 92). Activation of AhR by administration of 
a synthetic ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 
helps in the expansion of FoxP3-expressing iTreg cells. How 
the high-affinity AhR ligand FICZ promotes Th17 development 
while the low-affinity synthetic ligand TCDD promotes iTreg 
remains unresolved. It has been proposed that higher half-life and 
lower affinity of TCDD for AhR binding, compared to naturally 
occurring high-affinity ligand FICZ, accounts for its influence 
on FoxP3-expressing iTreg development. AhR promotes gene 
transcription by binding to a consensus dioxin response element 
(DRE) upstream of AhR-inducible genes. In the Foxp3 promoter 
as well as in promoters of various cytokine and cytokine receptor 
genes, including STATs, several DRE have been identified that 
are capable of binding AhR directly (91, 93). Therefore, a role 
for AhR in regulating STAT1 and STAT5 during Th17 and iTreg 
development has been proposed (90, 94, 95). The precise role of 
AhR in Th17 differentiation remains unclear but there is a distinct 
possibility that it might play a role in Th17 plasticity along both 
iTreg–Th17 and Th17–Th1 axes by influencing STAT5 and STAT1 
activation, respectively. Our own studies have shown that despite 
upregulation of AhR in Th17 cells, its activation does not directly 
influence IL-17 induction but plays a critical role in induction 
of IL-22 from Th22 cells (8). It is likely that AhR also supports 
low levels of IL-22 induction from Th17 cells but its additional 
role in other effector functions of Th17  cells requires further 
investigation.
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The importance of iL-1/iL-1R1 Signaling
Besides IL-6, IL-1/IL-1R1 signaling is considered to be essential 
for the differentiation and commitment of Th17  cells (76, 77). 
Although IL-1β alone induces IL-17 and RORγt from naïve 
human CD4 T  cells, IL-6 or IL-23 has a synergistic effect on 
IL-1β-mediated IL-17 induction. Mice deficient in IL-1R1 fail to 
induce IL-17 upon antigen challenge (96). IL-1R1-deficient mice 
are also resistant to EAE that is associated with a decrease in fre-
quency of Th17 cells (96, 97). After induction of EAE in a mixed 
chimera experiment, MOG-specific IL-17 cells are reduced in 
CNS in IL-1R1-deficient cellular compartment along with a 
significant increase in FoxP3-expressing cells (97). SIGIRR, 
a negative regulator of IL-1 receptor, also suppress Th17  cell 
expansion and Th17-mediated disease (98). IL-1 is also known 
to counter the inhibitory effect of IL-2 on RORγt and IL-23R 
expression during Th17 differentiation (99). It has been proposed 
that specific PAMPs induce APCs to promote IL-1β-mediated 
Th17 differentiation. While C. albicans, a pathogenic fungus, 
strongly induces both IL-6 and IL-1β from human monocytes, 
S. aureus, a pathogenic bacterium, induces IL-6 alone but not 
IL-1β, suggesting distinct signaling pathways are induced based 
on the nature of PAMPs recognized (32). Accordingly, neutrali-
zation of IL-1β completely abrogates C. albicans-induced Th17 
differentiation with marked reduction in RORγt level, whereas 
neutralization of IL-1β has a less severe effect on S. aureus-
specific Th17 development.
A clear mechanism to explain the role of IL-1 signaling in 
Th17 development has been evasive. Contradictory reports 
exist on the requirement of IL-1/IL-1R1 signaling pathways 
on intestinal Th17 differentiation based on studies on MyD88-
deficient mice (100, 101). But the studies investigating the role 
of IL-1β in intestinal Th17 development have been performed 
under steady-state conditions rather than under inflammatory 
conditions where IL-1β reaches its highest level. Moreover, it has 
also been argued that critical role of IL-1β in Th17 development 
during intestinal homeostasis has been obscured by the ex vivo 
stimulation of Th17  cells that exaggerate intracellular IL-17 
expression and provoke early commitment to IL-17 production 
before full effector status is achieved (30, 101). Therefore, the role 
of IL-1β in Th17 development during intestinal inflammation, 
particularly in disease models where Th17 cells are known to be 
protective, remains largely unknown. Recently, our group has 
demonstrated a novel role of IL-1β in modulating iTreg–Th17 
developmental axis during intestinal inflammation caused 
by enteropathogenic bacteria (26). We found that by down-
regulating SOCS3, IL-1β enhances the amplitude and duration of 
IL-6-driven pSTAT3 induction and alters the pSTAT3/pSTAT5 
balance in developing T cells to enhance Th17 cell development 
at the expense of iTreg cell development. As RA production is 
dominant in the gut microenvironment, IL-1/IL-1R signaling 
is critical to override dominant STAT5 signaling that supports 
a tolerogenic environment of the gut, thereby promoting Th17 
differentiation at the expense of iTreg development. Accordingly, 
in intestinal lymphoid tissues but not in other lymphoid tissues 
of IL-1R1-deficient mice, there is a skewed balance of FoxP3- and 
IL-17-expressing CD4 T cells with impaired Th17 differentiation. 
Therefore, it is likely that IL-1β becomes critically required for 
optimal differentiation of Th17 cells particularly in environments 
rich in RA, which otherwise suppresses Th17 development.
The emerging Roles of iRF4 and BATF
IRF4, a member of interferon-regulatory factor TF previously 
known to be associated with GATA3-mediated Th2 differentia-
tion, is required for Th17 cell differentiation (102, 103). Besides 
Th2 and Th17 differentiation, IRF4 is also essential for the 
development and function of IL-9-producing Th9 subset as well 
as development of effector Treg subset (104, 105). IRF4-deficient 
mice are resistant to EAE with a severely reduced frequency 
of Th17  cells (21). Although RORγt expression is markedly 
decreased in Irf4−/− T  cells following treatment with IL-6 and 
TGFβ, retroviral overexpression of RORγt fails to fully restore 
IL-17 production during Th17 development, suggesting that 
IRF4 might be upstream of RORγt. IRF4-deficient T  cells also 
express elevated Foxp3 levels under Th17 conditions, indicat-
ing that it might function to modulate RORγt/Foxp3 balance 
during iTreg to Th17 transition. It is unlikely that the impaired 
Th17 responses with reciprocal increase in numbers of Foxp3+ 
Tregs in IRF4-deficient animals is due its influence on STAT3 
signaling as STAT3 signaling remains intact in absence of IRF4. 
A converse relation between IRF4 and FoxP3 is also reported, as 
Foxp3 knockdown results in marked decline in IRF4 expression 
in Treg cells (106). Moreover, IRF4-deficient Treg cells selectively 
fail to suppress Th2 response (106). IRF4-deficient Th17 cells also 
produce high levels of IFNγ in addition to elevated FoxP3 levels 
under Th17 conditions, suggesting that the TF plays an important 
role in plasticity of Th17 cells along both iTreg and Th1 axes (20).
Another TF, basic leucine zipper transcriptional factor 
ATF-like or BATF, a member of the AP-1 transcription family, 
is also essential for Th17 differentiation (18). Although BATF is 
expressed in Th1, Th2, and Th17 cells, BATF-deficient CD4 T cells 
display normal Th1 and Th2 differentiation but highly reduced 
IL-17 production under Th17 conditions. BATF also directly 
controls expression of the Bcl-6 and c-Maf TFs, both of which are 
needed for development of follicular helper T cells (107). After 
dimerizing with JunB, BATF regulates transcriptional activation 
of several Th17-specific genes by binding to promoters and 
intergenic regions of the Il17a, Il17f, Il21, and Il22 genes. Similar 
to IL-6-deficient mice, BATF-deficient mice are resistant to EAE, 
but, unlike IL-6-deficient mice, BATF-deficient mice have normal 
frequencies of FoxP3+ CD4 T cells (18). However, despite com-
parable FoxP3 induction under iTreg condition, BATF-deficient 
T cells fail to downregulate Foxp3 in response to IL-6 and TGFβ. 
Similar to IRF4-deificency, retroviral overexpression of RORγt 
fails to restore IL-17 production in BATF-deficient Th17  cells, 
indicative of a potential synergistic interaction between RORγt 
and BATF. Nevertheless, unlike RORγt, absence of BATF prevents 
IL-6-mediated downregulation of FoxP3 despite intact STAT3 
signaling, suggesting that BATF-mediated antagonism of iTreg 
programming can be a mechanism of promoting Th17 differen-
tiation. Although overexpression of BATF in activated primary 
human T cells is known to decrease IL-2 production, neutraliza-
tion of IL-2 failed to restore IL-17 production in BATF-deficient 
CD4 T cells (108). Additional studies are needed to understand 
how IL-2 signaling affects Th17 differentiation in absence of 
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BATF via strengthening of counteractive FoxP3-dependent Treg 
programming during Th17 development. It is possible that during 
Th17 development, BATF restricts STAT5-mediated maintenance 
of FoxP3 expression via its suppressive effect on IL-2 induction, 
which results in downregulation of FoxP3, thereby preventing 
its inhibitory effect on RORγt. More recently, TCR signaling was 
found to promote assembly of IRF4/BATF complex on Il17a/f 
gene promoters, which makes the chromatin around this region 
more permissive to subsequent binding of lineage-specific TFs 
such as RORγt (23). As the assembly of IRF4/BATF is independ-
ent of Th17-polarizing cytokine-mediated signaling, these two 
TFs are designated as “pioneer” TFs, which promotes binding of 
subsequent lineage-specific cytokine-driven TFs to certain Th17-
specific gene loci. Exactly how BATF and IRF4 crosstalk with 
STAT3 to govern Th17 differentiation is not clearly understood 
at present. As these TFs are induced in Th0 cells, it is tempting 
to hypothesize that they prime T cells to differentiate along dif-
ferent lineages contingent on the cytokine environment. Thus, 
while TGF-β- and IL-6-induced signals recruit STAT3/RORγt to 
a subset of BATF/IRF4 binding sites in Il17a/f promoters that are 
made accessible by their binding, Th1 or Th2 signals may recruit 
STAT1/T-bet or STAT6/GATA-3 to the promoter regions of the 
respective subset-specific genes. However, assigning a solitary 
function to these TFs would be undermining their complexity 
as their effects extend to other related subsets along the Th17 
developmental axis.
The Lineage-Associated Roles of Runx1, 
Foxp3 and T-bet
Runt-domain class of TFs (Runx) represents another family of 
proteins that broadly regulate CD4 Th cell differentiation (109). 
Of the three mammalian Runt domain TFs, Runx1 is required 
for normal hematopoiesis, including thymic T cell development. 
Runx1 influences Th17 differentiation by directly inducing Rorc 
expression as well as binding co-operatively with RORγt to facili-
tate Il17 transcription (110). Runx1 also controls Treg function 
by co-operatively binding to FoxP3 to repress Il2 transcription 
(111). FoxP3, by binding to Runx1, also inhibits RORγt–Runx1 
complex-induced IL-17 expression. Therefore, a complex tripar-
tite interaction among RORγt, Foxp3, and Runx1 has been pro-
posed as a key regulatory mechanism governing balance between 
pro-inflammatory Th17 cells and anti-inflammatory Treg cells. 
In addition to the tripartite RORγt-Runx1–FoxP3 interaction, 
T-bet  also binds to Runx1 to inhibit Th17 differentiation and 
prevent productive association of Runx1 with Rorc without 
directly repressing the Rorc promoter (112). Overexpression of 
Runx1 reverses this inhibitory effect of T-bet on IL-17A produc-
tion by Th17 cells. Therefore, all three master TFs for iTreg, Th17, 
and Th1 subsets, namely, FoxP3, RORγt, and T-bet, physically 
interact with Runx1 to modulate transcriptional competence of 
Il17 gene.
RORγt and Foxp3 are co-expressed in naive CD4 T  cells 
exposed to TGFβ, and their co-expression is also found in a 
subset of intestinal CD4 T cells. During their development along 
iTreg–Th17 axis, Foxp3 inhibits the function of RORγt through 
an interaction involving the sequence encoded by exon 2 of 
FoxP3 (28). Pro-inflammatory cytokines such as IL-6, IL-21, and 
IL-23 relieve Foxp3-mediated inhibition of RORγt by suppress-
ing FoxP3 expression in a STAT3-dependent manner. Therefore, 
plasticity of a developing CD4 T cell along the iTreg–Th17 axis 
is determined by the relative abundance of pro-inflammatory 
cytokines in the surrounding milieu followed by interactions 
between FoxP3, Runx1, and RORγt. Along the iTreg–Th17 axis 
of differentiation, T-bet is the only master TF that remains in a 
transcriptionally poised bivalent chromatin state, consisting of 
both permissive and non-permissive epigenetic marks, in differ-
entiated iTreg as well as Th17 cells (113). Although several studies 
have indicated that Th17 responses are stronger in T-bet-deficient 
animals, T-bet is essential for generation of pathogenic Th17 cells 
(114–117). High T-bet induction is also necessary for differentia-
tion and function of pathogenic TGFβ-independent Th17  cells 
(74). Surprisingly, suppression of T-bet also inhibits expansion 
of Th17  cells under specific circumstance via downregulation 
of IL-23R (118). Therefore, under certain circumstances, T-bet 
induction can well be necessary for differentiation of pathogenic 
Th17 cells and can serve a more intrinsic role in differentiation of 
pathogenic Th17 cells in addition to regulating late developmen-
tal plasticity of Th17 cells.
TH17 PLASTiCiTY iN HUMAN iBD
The immune system of the intestine is largest immune system in 
the body. The gut harbors billions of microbes, and RA-driven 
fine-tuning of specialized immune cells ensure proper intestinal 
homeostasis. The commensal intestinal microbiota affects 
the intestinal immune system in such way that homeostasis 
is achieved by enforcing equilibrium between Treg cells and 
Th17 cells, which are the two largest populations of CD4 T cell 
subsets present in the gut at homeostasis. However, this balance 
may be disrupted by aggravated immune assault on commensal 
microbe or invasion of pathogenic microbe leading to either 
an augmented pro-inflammatory environment or a diminished 
anti-inflammatory environment, resulting in pathological 
conditions of the intestine. Gut-resident CD103+ DCs, which 
favor tolerogenesis at homeostasis via their interaction with the 
local microenvironment rich in RA and TGFβ as well as with 
the intestinal epithelial cells, break down their tolerance on 
additional TLR activation by pathogenic microbes or by other 
pro inflammatory stimuli during inflammation. Inflammatory 
conditions also provoke induction of various pro-inflammatory 
cytokines from APCs that impacts fate conversion of CD4 T cells 
along the iTreg–Th17, Th17–Th22, and Th17–Th1 developmental 
axes (Figure 3). Accordingly, several intermediate phenotypes of 
CD4 T cells co-expressing FoxP3/IL-17, IL-17/IL-22, and IL-17/
IFNγ are found in the intestine, mostly under inflammatory 
disease states.
Ulcerative colitis (UC) and CD are IBDs that are characterized 
by chronic inflammation of the intestine caused by an over-
reactive host immune response against microbes or food antigens 
(119, 120). Although the precise etiology of IBD remains unclear, 
unrestrained activation of effector CD4 T cells has been regarded 
as a key factor in the pathogenesis of IBD. In chronic inflamma-
tory diseases of the intestine, the balance of pro-inflammatory 
FiGURe 3 | Development of Th17 cell and its related intermediary cells during intestinal homeostasis and breakdown of homeostasis during 
inflammation or infection. During intestinal homeostasis, CD103+ dendritic cells (DCs) of the intestine are conditioned by epithelial-cell-derived factors like thymic 
stromal lymphopoietin or TSLP, IL-10, and TGFβ. Conditioned DCs maintain tolerance by active secretion of retinoic acid (RA) that predominantly promote the 
differentiation of FoxP3-expressing inducible regulatory T (iTreg) cells. This process can also be facilitated by commensal microflora (green elongated and blue 
circular) like Clostridum sp. and Bacteroides fragilis that promote a tolerogenic phenotype in the DC by inducing secretion of TGFβ and other factors from intestinal 
epithelial cells. During intestinal homeostasis, iTreg cells are most abundant in the colonic lamina propria. Once intestinal homeostasis is broken by invasion of 
pathogenic microorganism (yellow elongated and red elongated) like Citrobacter rodentium or other bacterial species, the epithelial barrier is destroyed leading to 
loss or alteration of epithelial cell-derived immunosuppressive factors. As a result of which the tolerogenic state of DC is altered by activation of additional toll-like 
receptor (TLR) that induces DC to secrete proinflammatory cytokines like IL-6, IL-23, IL-1β, and IL-12. Accordingly, with decreasing spatio-temporal concentration of 
RA and TGFβ and increasing concentration of proinflammatory cytokines like IL-6, IL-23, and IL-1β, an infectious or inflammatory state allows induction of Th17, 
Th22, and Th1 cells. The induction of proinflammatory cytokines also induces the transition of iTreg cells to Th17 cells via intermediary FoxP3 and RORγt-
coexpressing cells (iTreg–Th17). Reversion of Th17 cells to iTreg cells may also occur after resolution of inflammation. After maturation of Th17 cells, reduced TGFβ 
concentration may also lead to differentiation of Th22 cells via transitioning through AhR and RORγt co-expressing, intermediary Th17/Th22 cells that produce both 
IL-17 and IL-22 (Th17–Th22). Th22 cells can also transition to Th17 phenotype after being subjected to an environment supporting increased TGFβ concentration 
by shutting down IL-22 and initiating IL-17 production. During late Th17 development, chronic TCR stimulation of Th17 cells and/or the actions of IL-23 and IL-12 
prompt the Th17 cells to transition into Th1 cells via T-bet and RORγt co-expressing Th17/Th1 cells that produce both IL-17 and IFNγ (Th17–Th1). Th1 cells are 
mostly fully committed, terminally differentiated cells that attain a “fixed” phenotype without any further fate alteration.
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and regulatory cells plays a critical role in disease progression. 
Th17  cells are prevalent in IBD patients, who have increased 
IL-17A levels in their inflamed colonic mucosa (84, 121–123). 
Genome-wide association studies (GWAS) have indicated that 
IL-23R and at least five other Th17-associated genes are linked 
to susceptibility with CD (124–126). However, it is not clear how 
IL-23R polymorphisms predispose humans to CD by influencing 
Th17 differentiation.
Recent studies on developmental overlap among iTreg–Th17, 
Th22–Th17, and Th1–Th17 axes of cellular differentiation have 
compounded the problem of assigning specific functions of 
Th17 cells in the pathogenesis of IBD. At homeostasis, the intes-
tine harbors an abundance of Treg cells. Patients with mutations 
in FoxP3 that result in non-functional or reduced numbers of 
Treg cells, suffer from severe intestinal inflammation (127). 
However, both CD and UC patients have increased numbers of 
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FoxP3-expressing iTreg cells in their colonic lesions compared to 
non-inflamed areas, indicating that inflammation rarely results 
from a decrease in FoxP3-expressing iTreg population in human 
intestine (128). Although Treg cells are efficiently recruited to the 
inflamed colonic mucosa in IBD patients, it is possible that the 
function of iTreg cells might be compromised if they differenti-
ate into Th17 cells as significantly higher prevalence of IL-17 and 
FoxP3 double-expressing CD4 T cells have been found in IBD 
patients (86). Compared to FoxP3-expressing cells alone, the 
IL-17 and FoxP3 co-producing population exhibit highly reduced 
suppressive ability. Alternatively, a prompt Th17 response arising 
from transitioning iTreg cells can also be beneficial under specific 
circumstances where Th17 cells have a protective role to play in 
eradicating pathogenic organisms and limiting inflammation. 
Studies from our group have shown that a failure in conversion 
of FoxP3-expressing iTreg cells into Th17 cells during enterobac-
terial infection in mice results in impaired bacterial clearance 
and enhancement of intestinal inflammation. Therefore, plastic-
ity of Th17  cells along the iTreg axis can profoundly affect the 
disease outcome in patients where either failure of intermediate 
FoxP3+IL-17+ cells to gain effector Th17 function or their failure 
to suppress effector function can aggravate the inflammatory 
function in a context dependent manner.
The exact role of Th22 cells in the pathogenesis of CD and 
UC is unclear. After the developmental and functional charac-
terization of Th22 cells, it was recognized that IL-22-producing 
CD4 T cells might comprise a population that is distinct from 
Th17  cells (8). Whereas Th17  cells promote recruitment of 
neutrophils and participate in tissue repair, Th22 cells promote 
mucosal healing through epithelial proliferation, restoration 
of epithelial barrier, and induction of antimicrobial molecules. 
GWAS in UC patients has identified a polymorphism located in 
chromosome 12,137 kb upstream of the IL22 gene, suggesting a 
possible association of IL-22 expression with UC susceptibility 
(129). Although IL-22 is not detectable in the colonic mucosa 
of normal human subjects, IL-22 expression is readily detectable 
from CD4 T  cells in the colonic mucosa of IBD patients. The 
frequency of IL-22-producing cells is increased in UC patients as 
well as CD patients, indicating a possible pro-inflammatory role 
in etiology of IBD (130, 131). However, a beneficial role for IL-22 
has recently been suggested in human IBD (132). It was found that 
IL-17-producing Th17 cells alone are enriched in inflamed por-
tions of the colon of IBD patients with a relative decline in Th22 
cells that exclusively produce IL-22. Nevertheless, the decrease 
in Th22 cells observed during active inflammation is correlative 
and whether or not this is important for disease pathogenesis 
is currently unknown. Although, in acute intestinal inflamma-
tion Th22 cells are protective, careful studies need to be done 
to determine their function in chronic intestinal inflammation. 
It is also confounding that these two lineages developmentally 
overlap and one can arise out of the other along the Th17–Th22 
axis: neutralization of TGFβ under Th17 condition completely 
suppresses IL-17 production and enhances IL-22 induction. 
During acute intestinal inflammation, IL-22-producing CD4 
T cells emerge earlier than IL-17-producing CD4 T cells in the 
colonic lamina propria, indicating that Th17 cells might emerge 
as an offshoot of the Th22 differentiation pathway contingent on 
enhanced production of TGFβ (8). Although high levels of active 
TGFβ are produced in the inflamed tissues of IBD patients, it 
is not sufficient to stop mucosal inflammation (133). Indeed, 
in biopsies of UC patients where a selective depletion of Th22 
was noted, TGFβ transcript expression was significantly higher 
compared to normal tissue of healthy controls, indicating that the 
TGFβ may play a role in preventing differentiation of Th22 cells 
in inflamed intestinal tissue of IBD patients (132).
The phenomenon of Th17 plasticity gives rise to another 
unique conundrum. During late development, Th17  cells can 
transition to IFNγ-producing Th1-like Th17 cells. CD, originally 
defined as a Th1-mediated pathology, has been recently reclas-
sified as a Th17/Th1 phenomenon where mucosal tissue from 
patients has been found to produce IL-17 in addition of IFNγ 
(121, 134). Based on previous studies, it has been proposed that 
this ability of Th17 cells to transition into Th1 cells is a central 
mechanism that exacerbates immunopathology and that Th17/
Th1 (ex-Th17) cells rather than Th17  cells alone play a critical 
role in IBD pathology (29, 30). In Th17-driven IBD, transition of 
Th17 precursors to Th1-like cells is absolutely required for dis-
ease, because Th17 cells deficient in IFN-γ or T-bet fail to induce 
intestinal inflammation (31). In CD patients, Th17 cells are found 
to produce both IL-17 and IFNγ, suggesting that Th17 plasticity 
contribute to disease pathogenesis (84). However, a therapeutic 
trial of administration of an anti-IL-17A monoclonal antibody to 
patients with moderate to severe CD had no therapeutic effect, 
and exacerbated the disease in some patients, suggesting a protec-
tive role of IL-17A in CD (135). It is tempting to speculate that 
Th17 cells and “Th1-like” Th17 cells might have disparate func-
tions where “stable” Th17  cells are protective while “Th1-like” 
Th17 cells are pathogenic. In this scenario, immunological thera-
pies aimed at depletion of IL-17-producing T cells might lead to 
adverse effect, as the beneficial Th17 cells will also be targeted. 
Therefore, unless the functions of these overlapping subsets are 
more clearly defined in IBD, generalized therapies might affect 
other developmental arms of Th17 cells due its inherent plasticity 
and overlap with related subsets of Th and regulatory T cells.
The iTreg–Th17 Axis
The balance between factors promoting iTreg development 
and Th17 development is critical in determining homeostatic 
versus inflammatory condition in the intestine. As the early 
developmental programs of iTreg and Th17 cells are intimately 
linked, it is not surprising that intermediate phenotype along the 
iTreg–Th17 developmental axis exists in vivo. RORγt and FoxP3 
co-expressing CD4 T cells are readily detected in the intestinal 
lamina propria (28, 136). Interestingly, in iTreg cells, differenti-
ated in presence of TGFβ, both RORγt and FoxP3 are induced 
but FoxP3 via exon 2-encoded peptide inhibits RORγt activity 
through a protein–protein interaction (28, 136). During Th17 dif-
ferentiation, action of pro-inflammatory cytokines such as IL-6 
suppresses Foxp3 induction resulting in upregulation of RORγt 
expression. Although the competitive antagonism between 
FoxP3 and RORγt may negatively influence Th17 differentiation, 
expression of FoxP3 during early development stage may be 
integral part of Th17 differentiation as a substantial percentage 
of IL-17-producing CD4 T  cells in the colon express FoxP3 at 
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one time during their development (28). Purified FoxP3+ cells 
emerging during iTreg differentiation can differentiate into IL-17-
producing cells when subjected to Th17 differentiation program 
(66). Similarly, human iTregs can differentiate into Th17  cells, 
particularly when exogenous IL-1β or IL-23 is present (137). RA, 
a vitamin A metabolite produced copiously by intestinal DC, 
favors FoxP3+ iTreg development by constraining Th17 devel-
opment in an IL-2-dependent pathway (25, 26). RA signaling, 
mediated through intracellular retinoic acid receptors expressed 
in T cells, blocks the inhibitory effect of IL-6 on FoxP3 induction, 
thereby accentuating inhibitory effect of FoxP3 on RORγt (138). 
Additionally, RA can directly inhibit RORγt in CD4 T cells (139). 
RA can not only reciprocally modulate iTreg and Th17 differ-
entiation but can also reverse the Th17 developmental program 
by converting it to FoxP3-expressing iTregs. Human myeloid-
derived suppressor cells are able to convert fully differentiated 
Th17 T cells to FoxP3+ iTreg cells in a RA- and TGFβ-dependent 
pathway (140). Thus iTreg–Th17 axis of differentiation is more 
dynamic in nature than usually appreciated. In the process of 
investigating lineage association between iTreg and Th17  cells, 
study from our group has revealed a complex signaling network 
where IL-1 signaling crosstalks with tolerogenic RA signaling to 
modulate conversion along iTreg–Th17 developmental axis (26). 
A developing FoxP3-expressing iTreg cell, fortified with amplified 
pSTAT5 signaling by RA, has the ability to retain a dormant Th17 
programming where IL-1 signaling-mediated amplified pSTAT3 
expression becomes critical to shift the balance in favor of Th17 
differentiation pathway during intestinal inflammation. This 
is primarily achieved via two newly discovered pathways—(a) 
direct enhancement of IL-2/STAT5 signaling in CD4 T cells by 
RA and (b) NF-κB-dependent SOCS3 repression by IL-1 result-
ing in sustained pSTAT3 signaling. Indeed, by favoring repressive 
pSTAT3 binding over pSTAT5 binding at an intronic enhancer 
of the Foxp3 gene, IL-1-dependent potentiation of IL-6-driven 
STAT3 signaling directly subverts the Treg-stabilizing function of 
IL-2/STAT5 promoted by RA, thereby contributing to plasticity 
in the iTreg developmental program. This phenomenon explains 
why a substantial fraction of IL-17-producers in the intestinal 
lamina propria are found to express FoxP3 during their develop-
ment. Pathogen-driven contraction of iTreg population with their 
concomitant conversion to Th17 cells in the gut lamina propria, 
might be effective to break tolerogenic environment of the gut, 
which otherwise would dampen the effector response required 
to thwart an invading microbe. Therefore, invoking conversion of 
the iTreg to Th17 effector cells would allow the fastest and most 
efficient generation of the intestinal effector response. Recently, a 
study has shown that Th17 cells can reversibly transdifferentiate 
into regulatory T cells during resolution of intestinal inflamma-
tion, which is contingent on AhR signaling (141). Therefore, fate 
commitment along the iTreg–Th17 developmental axis, besides 
depending on the interaction between lineage-specific TFs, is also 
governed by lineage-associated TFs. Besides fate inter-conversion 
between iTreg and Th17 lineages, late developmental axis of 
both subsets is also tied to Th1-like developmental program. 
Chromatin conformation of Tbx21 locus remains in a transcrip-
tionally poised state in both differentiated iTreg and Th17 cells. 
Accordingly, myelin-reactive IL-12-conditioned iTregs lose 
Foxp3 expression and express both T-bet and IFN-γ in a manner 
akin to Th17 to Th1 conversion (142). Therefore, plasticity along 
the iTreg–Th17 developmental axis also extends to Th1 subsets 
contingent on specific stimulatory conditions.
The Th17–Th22 Axis
IL-22 belongs to the IL-10 family members of cytokine that is 
produced from innate immune cells as well as CD4 T cells and 
is assuming growing importance for its immunoregulatory 
functions in infection, inflammation, autoimmunity, and cancer 
(143). Like its sibling IL-10, divergent types of immune cells 
produce IL-22. A systematic study using cognate stimulation for 
different types of human immune cells-APC, NK, and T  cells, 
indicated that CD4 T cells are the major producers of IL-22 (144). 
Initially IL-22 was identified as a Th1 cytokine in humans. Later 
on, Th17  cells were known to be the main producers of IL-22 
that was co-expressed along with IL-17A and IL-17F (145, 146). 
However, the production of IL-22 by Th17  cells is somewhat 
counterintuitive, as TGFβ, which is critical for optimal Th17 
differentiation, strongly inhibits IL-22 induction. However, a 
recent study demonstrated a TGFβ-independent pathway of 
Th17 differentiation that co-produced IL-17 and IL-22 along 
with high induction of T-bet, suggesting that a divergent lineage 
of Th17 cells can indeed produce IL-22 (74). Influence of T-bet 
on IL-22 induction was also reported by another study where 
retroviral transduction of T-bet in Th17 cells resulted in higher 
induction of IL-22 but downregulation of IL-17 (112). AhR and 
c-Maf are the two critical TFs that have been identified, which 
are responsible for induction of IL-22 from Th17 cells (22, 147). 
Nonetheless, later studies on human cells demonstrated exist-
ence of Th22 cells that exclusively produce IL-22 without IL-17 
production (148–150). IL-23 was believed to be the principal 
cytokine required for IL-22 induction from Th17  cells despite 
the fact that IL-23 is dispensable for differentiation of Th17 cells 
(27). The conundrum was addressed in our study, which reported 
that IL-6, not IL-23, is the critical cytokine required for optimal 
differentiation of host-protective IL-22-producing Th22 subsets 
during Citrobacter rodentium-induced infectious colitis. It 
emerges that akin to shared requirement of TGFβ for iTreg and 
Th17 development, IL-6 is a common cytokine that is essential for 
driving both Th17 and Th22 differentiation. Moreover, as neutral-
izing TGFβ under Th17 conditions restores IL-22 induction, it is 
likely that Th17 and Th22 evolve from a common differentiation 
pathway. Curiously, emergence of IL-22-producing CD4 T cells 
in inflamed colonic lamina propria precedes development of 
IL-17-producing CD4 T cells during infectious colitis, indicating 
toward a possible biphasic development where an early “Th22” 
developmental phase is followed by late “Th17” phase contingent 
on local concentration of TGFβ. This aspect of early induction of 
IL-22 followed by late induction of IL-17 can also be ascribed to the 
differential activation of divergent TFs responsible for sequential 
induction of IL-22 and IL-17 induction from the same cell during 
its development. Comparative transcriptome analysis of Th22 and 
Th17 cells reveals differential expression of several hundred genes, 
among which are lineage-specific TFs such as T-bet and RORγt 
that are reciprocally regulated between these two subsets. This 
reciprocal regulation of Tbx21 and Rorc expressions during Th22 
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and Th17 development is consistent with the role of TGFβ that 
suppresses T-bet and enhances RORγt. Despite the lower levels of 
AhR induction in Th22 cells compared to Th17, AhR contributes 
significantly to IL-22 expression in Th22 cells such that combined 
loss of T-bet and AhR actions results in complete abrogation of 
IL-22 expression. It is likely that AhR promotes transcriptional 
regulation of IL-22 in both Th17 and Th22 cells via binding to 
its cognate DRE present in Il22 promoter. The observed interplay 
of AhR and T-bet in maximizing IL-22 production from Th22 
cells also offers a possibility that IL-22 can also be produced by 
Th1 subsets in accordance to the original description of IL-22 
as a product of human Th1  cells (144). As IL-23 induces both 
STAT3 and STAT4 in Th17 cells, the enhancing effect of IL-23 on 
IL-22 induction from both Th22 and Th17 cells might be partly 
explained by acquisition of IL-23-mediated Th1 competence in 
these cells. Accordingly, most of the IL-22-producing CD4 T cells 
of lamina propria co-express T-bet during infectious colitis 
(151). It is likely that IL-22-expressing Th17 cells are a distinct 
population compared to IL-22 expressing Th22 cells as inhibition 
of TGFβ signaling during infectious colitis specifically depletes 
IL-22-producing Th17 cells but increases the frequency of IL-22-
producing Th22 cells (151). However, the functional specificities 
of IL-22-producing Th22 and Th17  cells remain unknown. In 
this regard, it is also important to note that Th22 cells express 
significantly lower levels of Rorc compared to Th17 cells sugges-
tive of a supporting role of RORγt in IL-22 induction from Th22 
cells. Despite validation of a protective role of IL-22-producing 
CD4 T cells in acute colitis, paradoxically it can also contribute 
to intestinal pathology during chronic colitis. IL-22-producing 
CD4 T cells are found to be pathogenic in a model of chronic 
colitis (152). Th22 cells are also found to be pro-inflammatory in 
the gastric mucosa of Helicobacter pylori-infected patients (153). 
However, a protective role of IL-22 has also been reported in IBD 
patients as reciprocal increase in Th17 and decrease in Th22 cell 
has been noted in inflamed colonic mucosa of patients due to 
increased levels of active TGFβ, which leads to loss of Th22 cells 
from the intestinal mucosa resulting in epithelial injury (132). 
Further studies are needed to understand plasticity and lineage 
relationship between Th17 and Th22 subsets in human IBD along 
with their individual roles in inflammation.
The Th17–Th1 Axis
Although proximal signals governing Th1 development is clearly 
distinct from signals required for Th17 differentiation, commit-
ted Th17 cells can be induced to produce IFNγ by repeated TCR 
stimulation or on exposure to IL-12 (29). Th17 cells differentiated 
from naive CD4 T cells on re-stimulation yielded progeny that 
were a heterogeneous mix of cells expressing IL-17A, IL-17F, and 
IFNγ, either singly or in combination. However, re-stimulation 
in presence of exogenous TGFβ alone led to sustained expression 
of high IL-17A and IL-17F, while IL-23 failed to maintain IL-17A 
and IL-17F expression. Addition of exogenous IL-12 completely 
silenced IL-17A and IL-17F expression from Th17 cells, which 
rapidly transitioned into IFNγ-producing Th1-like cells in a 
STAT4 and T-bet dependent manner as the absence of the TFs 
prevented the transition. Later ChIP-Seq studies found out that 
plasticity of Th17  cells can be partly attributed to poised state 
of Tbx21 locus in Th17 subset as permissive chromatin marks 
are retained in Tbx21 locus of differentiated Th17 cells (113). It 
has also been confirmed that T-bet expression by Th17 cells is 
indeed required for colitis pathogenesis where IL-23 produced 
by innate cells of the intestine acts on developing Th17 cells to 
deviate their differentiation to Th1-like cells by upregulating 
T-bet, through a mechanism that is largely Stat4 dependent 
(31). Remarkably, Gata3 locus also carries permissive chromatin 
marks in Th17 cells. Therefore, the obvious question to ask is why 
Th17 cells do not transition into Th2 cells? Indeed in a study it 
has been shown that in vitro differentiated Th17 cells can revert 
to both IFNγ-producing Th1 and IL-4-producing Th2 cells under 
Th1 and Th2 polarizing conditions (154). However, Th17  cells 
generated in vivo are often resistant to cross differentiation under 
Th1 and Th2 conditions (154). This suggests that the Th17 cells 
may have undergone pathways of differentiation in vivo that dif-
fer from those differentiated in vitro. Nevertheless, many human 
Th17 clones produce IFNγ and studies performed in humans 
clearly demonstrate the existence of Th1-like Th17 cells in both 
peripheral blood and gut tissues (84). Human Th17 and Th17/
Th1 clones are similar in nature as they express IL-23R, RORγt, 
IL-12Rβ2 chain and T-bet. Similar to mouse Th17 cells, stimula-
tion of human Th17 clones with IL-12 downregulated RORγt and 
upregulated T-bet and enabled the cells to produce IFNγ (84). 
In a fate-reporter mouse-based study, generated for tracking the 
fate of Th17 under inflammatory condition, almost all of the 
IFNγ-producing CD4 T  cells in the spinal cord were found to 
be ex-Th17 cells (30). Th17 to Th1 conversion depends on IL-23 
signaling that is required for the switch from IL-17A to IFNγ 
production during chronic inflammation. Transcriptional profile 
of Th17/Th1 cells drastically differs from conventional Th1 cells 
indicative of their dissimilar origin and function (155). On com-
paring the transcriptome signature of tyrosinase-related protein 
1 (TRP-1)-specific Th1 and Th17 cells before and after adoptive 
transfer, transcriptome of these Th1/Th17  cells also differed 
markedly from classical Th1 cells despite induction of IFNγ and 
T-bet. Importantly, a population of transferred TRP-1-Th17 cells 
showed self-renewal capability and retained the capacity of 
sustained production of IL-17 without IFNγ co-production. This 
suggests that multipotency of Th17, capable of differentiating into 
Th1-like effector like progeny (Th1/Th17) as well as self-renewing 
IL-17-producing cells (Th17), are advantageous for host for 
tumor eradication. Based on the intrinsic association of T-bet 
with late Th17 developmental program, one cannot exclude the 
fact that T-bet might serve as an essential co-factor in develop-
ment of pathogenic Th17 cells. Permissibility of Tbx21 promoter 
in non-Th1 subsets indicates partial redundancy of T-bet in 
IFNγ transcription, as IFNγ locus remains non-permissive in 
Th17  cells. It has been suggested that T-bet plays a larger role 
than merely facilitating IFNγ transcription (156). Accordingly, 
T-bet-deficient mice are resistant to EAE whereas IFNγR−/−, 
IL-12Rβ2−/−, and IL-12p35−/− mice, all of which lack critical 
components of the Th1-IFN-γ pathway, are highly susceptible to 
autoimmune diseases (157–161). Consistent with the notion of a 
wider unappreciated role of T-bet in Th17 differentiation, inhibi-
tion of T-bet suppresses the differentiation and/or expansion 
of myelin-specific Th17 cells and T-bet is found to be a critical 
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factor for establishing the encephalitogenicity of Th17 cells (117). 
Therefore, T-bet induction might be necessary for plasticity of 
Th17 cells as well as the differentiation of pathogenic Th17 cells.
ePiGeNeTiCS OF TH17 DiFFeReNTiATiON 
AND iTS ReLATiON TO PLASTiCiTY
Epigenetic modifications denote heritable changes in gene 
expression by selective positioning of nucleosome that consists 
of two units of histones—H2A, H2B, H3, and H4—without any 
change in nucleotide sequence (162, 163). During Th differentia-
tion, binding of lineage-specific TF to its cognate genes not only 
depends on its own induction but also on its accessibility to the 
cognate DNA binding elements, which is regulated by epigenetic 
modifications. Therefore, epigenetic changes modulate transcrip-
tion of key genes linked to a specific Th lineage via alteration 
of their chromatin architecture, which can be permissive (tran-
scriptionally accessible) or non-permissive (transcriptionally 
repressed). Following TCR ligation, major epigenetic changes are 
initiated by “pioneer” TFs and transduction of cytokine-driven 
STAT signaling. Lineage-specifying TFs subsequently act on the 
altered chromatin landscape brought about by STAT proteins and 
“pioneer” TFs to drive specific changes in gene expression. It is 
also being increasingly recognized that regulation of chromatin 
is a highly dynamic process that is kinetically altered during dif-
ferentiation of T cell subsets.
One of the most studied epigenetic modifications on various 
Th lineages is methylation of specific histone proteins at specific 
lysine residues (72, 113, 164, 165). While histone trimethyla-
tion of H3K4 (H3K4me3) increases chromatic accessibility and 
transcriptional competence of a gene, trimethylation of histone 
H3K27 (H3K27me3) decreases chromatin accessibility and 
reduces transcriptional competence of a gene. Formation of 
DNase1 hypersensitivity sites in candidate loci of Th cells is 
another hallmark of transcriptionally active chromatin structure 
that can be mapped to functionally demarcate regulatory regions 
of genes where epigenetic changes have occurred (166). Besides 
methylation, histone acetylation is also critical for chromatin 
structure and associated with transcriptional competence 
of a gene. Acetylation of lysine 27 residue of histone H3 is a 
commonly studied epigenetic mark that is associated with 
active chromatin architecture. Several other forms of histone 
modifications affecting transcriptional competence also exist 
but have been less extensively studied in Th lineages. H3K4me3 
and H3K27me3 epigenomes have been globally mapped in Th1, 
Th17, and iTreg susbets (113). Surprisingly, histone methylation 
patterns for lineage-specific TF genes exhibit both repressed and 
accessible epigenetic marks in unrelated subsets where they are 
not expressed. Tbx21, which encodes T-bet, a lineage-specific TF 
for Th1 subset, remains in a poised bivalent state in Th17 cells 
as well as iTreg cells, showing both repressive and permissive 
epigenetic modification in its locus. On the other hand, Rorc and 
Foxp3 completely lacked permissive epigenetic modification in 
unrelated Th subsets such as Th1 and Th2 subsets. The bivalent 
epigenetic modification of Tbx21 in Th17 and iTreg cells is con-
sistent with the observed plasticity of these two subsets and their 
propensity to transition to Th1 subset. Besides remaining in a 
transcriptionally poised state during Th17 differentiation, T-bet 
can directly participate to alter permissive epigenetic marks in 
Rorc locus. T-bet binds directly at a specific region of Rorc locus 
in differentiated Th17 cells treated with IL-12 (72). IL-12 stimu-
lation decreased permissive H3K4 methylation at Rorc locus, 
whereas TGFβ-stimulated cells retained H3K4 methylation—an 
effect that was reversed in the absence of T-bet. Therefore, epi-
genetic modifications influence Th17 differentiation at multiple 
levels encompassing the signature cytokine genes of Th17 subsets 
as well as TFs that regulate lineage plasticity. A global methyl-
ome analysis revealed that number of demethylated regions in 
Th17 cells far exceeds the number of demethylated regions pre-
sent in Th1 cells (167). Th17 cells display an even greater number 
of demethylated regions compared to naïve T  cells, suggesting 
that the high degree of demethylation might contribute to the 
plasticity of the Th17 cells.
Besides the master TFs, phosphorylated forms of STAT pro-
teins also bind to their cognate gene locus and modulate epige-
netic marks (168). pSTAT3 and pSTAT5 can bind to seven shared 
sites scattered in the promoters of the Il17a and Il17f genes as well 
as at distal locations relative to transcription initiation site (168). 
While binding of pSTAT3 correlated with permissive chromatin 
modifications associated with histone acetylation and H3K4me3 
marks, pSTAT5 acted as a repressor of Il17 transcription as its 
binding correlated with repressive chromatin modification. Of 
note, pSTAT5 binds directly to Il12rb2 and Tbx21 loci to facilitate 
Th1 differentiation (169). Therefore, how pSTAT5 binding can act 
both as activator and repressor of genes via alteration of epige-
netic marks remains to be identified. BATF, another TF essential 
for Th17 differentiation, binds to conserved intergenic elements 
in the Il17a/f locus as well as directly to promoters of Il17a, Il21, 
and Il22 genes (18). One of the BATF binding elements at the 
promoter region of Il17a gene directly overlaps with an identi-
fied Rorc binding element, suggesting that these two TFs interact 
by forming a stable ternary complex with DNA to modulate or 
stabilize transcriptional machinery of the Il17a gene. BATF, in 
conjunction with IRF4, also influences global histone acetyltrans-
ferase (p300) occupancy in Th17 cells, which is highly diminished 
in Batf−/− and Irf4−/− Th17 cells (23). However, RORγt deficiency 
had limited effects on p300 recruitment and H3K4 trimethylation, 
suggesting that it lacks a major role in epigenetic modification of 
its regulated genes. The co-operative binding of STAT proteins 
and the “pioneer” TFs followed by the binding of master TF not 
only determine the faithful transcriptional competence of their 
cognate loci but also ensure the maintenance of transcriptional 
competence through subsequent mitotic divisions. However, 
actions of other regulatory proteins during Th17 differentiation 
might disrupt the faithful maintenance of transcriptional compe-
tence through cell divisions by altering the epigenetic marks and 
contribute to Th17 plasticity.
TH17 PLASTiCiTY: iN SeARCH OF A BONA 
FiDe TH17 CeLLS
If the original genetic makeup of a Th17  cell is irrevocably 
lost during an effector response due to its plasticity, how can 
there be an existence of a memory Th17 cell with its bona fide 
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characteristics? How would the transitioned Th17  cells behave 
during a recall response? How is a Th17 program re-initiated 
upon re-encounter of a pathogen? In the context of these queries, 
one must distinguish between an infectious and autoimmune 
setting where Th17  cells play a role in disease pathogenesis. A 
study has shown that plasticity of Th17  cells along Th17–Th1 
axis differed between inflammatory and autoimmune conditions 
(30). In contrast to the altered fate exhibited by Th17 cells during 
EAE where erstwhile Th17 cells cease IL-17A expression and gain 
IFNγ expression, acute fungal infection with C. albicans gives rise 
to Th17 cells that do not deviate to IFNγ-producers. The apparent 
difference in plasticity of Th17 cells under infectious and autoim-
mune conditions might be due to the longevity of the effector 
response. While microbes can be rapidly cleared from the system 
by a potent Th17 response that subsides with clearance, chronic 
stimulation of Th17 cells promotes an alternative fate. Accordingly, 
a single intranasal infection with Streptococcus pyrogenes gives 
rise to Th17  cells that exclusively produce IL-17 without IFNγ 
co-production, whereas repeated infection results in emergence 
of IL-17/IFNγ double producers (170, 171). Moreover, intranasal 
vaccination with Klebsiella pneumoniae leads to a dominant 
Th17 response with no change in IFNγ-producing population. 
Importantly, during a memory response, protection against 
Klebsiella was dependent on IL-17, but not on IFNγ, suggesting 
that protection was mediated by “committed” Th17 cells (171). 
This evidently shows, albeit indirectly, that a stable Th17 memory 
population can indeed be generated. Therefore, continued TCR 
activation of Th17 cells would have a bearing on the stability of 
the Th17 cells.
On comparing the fates of endogenously generated memory 
Th1 and Th17 subsets to bacterial infection, it has been found that 
Th1 cells induced by intravenous infection are more efficient at 
entering the memory pool than Th17 cells induced by intranasal 
infection (172). It was suggested that Th17-mediated immunity 
is short-lived because IL-17A-producing CD4 effector T cells do 
not survive to become memory cells. However, the possibility that 
some Th17 cells simply transitioned to Th1 and lost the capacity 
to produce IL-17A was not ruled out in this study. On the other 
hand, it has also been proposed that Th17 cells represent an “ear-
lier,” less-differentiated, plastic and more stem cell-like state than 
Th1 cells. While investigating the anti-cancer responses mediated 
by Th17-polarized cells that effectively eradicated established 
tumors, it has been found that the acquisition of type 1 effector 
properties, including T-bet expression and the secretion of IFNγ 
in vivo, was required for the antitumor activity of Th17 cells (155). 
Whereas IFNγ-producing Th1 cells are terminal effectors prone 
to apoptosis that are short-lived and incapable of mounting a 
sustained antitumor effector response, Th17 cells are long-lived 
cells capable of maturational plasticity, which enables them to 
mount a sustained antitumor response.
Additionally, the initial priming cytokine environment dur-
ing an inflammatory or autoimmune response can contribute 
to the fate determination of Th17 cells. This is demonstrated by 
the fact that Candida-specific Th17 differentiation, initiated in the 
presence of IL-12-producing fungal antigen-stimulated mono-
cytes, produced significantly more IL-17/IFNγ co-producing 
cells than bacterial antigen-specific Th17  cells differentiated in 
presence of bacterial antigen-stimulated monocytes producing 
undetectable levels of IL-12 (32). Therefore, during the initiation 
of Th17 development in a given milieu, the relative abundance of 
Th17-promoting cytokines (IL-6, IL-1, IL-23, and IL-21) versus 
the Th17 inhibiting cytokines (IL-12, IL-27, IFN-γ, and IL-33) 
might well be instrumental in determining extent of plasticity of 
the developing Th17  cells. Contingent on their initial cytokine 
milieu, different populations of Th17 clones (stable or plastic) 
might emerge displaying intermediate stages of differentiation. 
Accordingly, a Th17 memory response can invoke proliferation of 
a stable IL-17-producing phenotype or a plastic IL-17 and IFNγ-
co-producing phenotype. Hence to unravel the mystery of Th17 
fate commitment with greater finesse, an all-inclusive approach 
needs to be taken to understand plasticity of Th17  cells where 
variables such as nature of APC, strength of TCR, and costimula-
tion, physiologically relevant concentration of pro- and anti-Th17 
cytokines are carefully considered.
CONCLUSiON AND PeRSPeCTiveS
After its encounter with the priming microenvironment 
consisting of diverse APCs, a multitude of antigens and other 
microenvironmental factors, the journey of a native CD4 T cell 
toward becoming an antigen-specific Th17  cell can be broadly 
divided into three sequential terrains. During its journey through 
the first terrain, strength of TCR–pMHC interaction, strength 
of costimulation and other “non-cytokine”-induced factors 
co-operate with APC-generated cytokines (e.g., IL-6) to induce 
STAT proteins (e.g., STAT3, STAT1) and “pioneer” TFs such as 
BATF and IRF4. STAT proteins and pioneer TFs collaborate to 
initiate the lineage-specific developmental program by induction 
of STAT-responsive and IRF4/BATF-responsive genes, which 
include the lineage-specific master TF, RORγt. During its journey 
through the second terrain, STAT3-induced RORγt co-operates 
jointly with the “pioneer” TFs to alter chromatin accessibility of 
key Th17-related genes by epigenetic modification for making 
them transcriptionally permissive. In its final passage through the 
third terrain, an orchestration of complex networking of signal-
ing events modulated by lineage-specific master TF, RORγt along 
with lineage-associated TFs (e.g., Runx1, AhR, and c-Maf), deter-
mines the stability of the Th17 developmental program through 
integration of various pro-inflammatory and anti-inflammatory 
environmental cues. Plasticity of Th17 cells is determined by the 
interplay of these variable factors acting across the three terrains.
The phenomenon of Th17 plasticity takes into account three 
distinct possibilities: (a) Th17 cells are inherently plastic in nature 
and are rarely terminally differentiated, (b) longevity of the Th17 
effector response (“acute” versus “chronic”) determine develop-
ment of “stable” versus “plastic” Th17 cells, and (c) initial priming 
environment of differentiating Th17 cells dictates Th17 plasticity. 
Taking into account all the three possibilities, the following unify-
ing explanation can serve to formulate a likely model illustrating the 
journey of naïve CD4 T cell through the iTreg–Th17, Th17–Th22 
and Th17–Th1 development axes. During iTreg differentiation, 
both FoxP3 and RORγt are induced by TGFβ alone where FoxP3 
effectively suppresses RORγt via protein-protein interaction to 
prevent initiation of Th17 programming. Any pro-inflammatory 
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